ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1312

Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study

Satoshi Inotani1,2,3,4, Yoshinori Taniguchi5, Takashi Karashima6, Yasuhiko Yoshinaga7, Hirofumi Nishikawa8, Natsuki Maeda9, Shimpei Fujimoto8 and Yoshio Terada10, 1internal medicine, Chikamori Hospital, Kochi, Japan, 2Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi medical school, Nankoku, Japan, 3Urology, Kochi medical school, Nankoku, Japan, 4Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, 5Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, 6Urology, Kochi University, Nankoku, Japan, 7Kurashiki Medical Center, Kurashiki, Japan, 8Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, 9Endocrinology,Metabolism,Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, 10Kochi University, Nankoku, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Enthesitis, Reactive arthritis, spondylarthritis and uveitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Infection-related Rheumatic Disease - Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  To evaluate the incidence of reactive arthritis (ReA), uveitis and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy (iBCG).

Methods:  The clinical symptoms, laboratory, and imaging findings of Japanese patients who received iBCG (n=555 (250 and 305 in Kochi Medical School Hospital (KMSH) and Kurashiki Medical Center (KMC), respectively)) for bladder cancer from March 1997 to February 2016 (for 20 years) were retrospectively assessed. Especially, the patients with ReA and conjunctivitis/uveitis were examined.

Results:  The backgrounds of patients received iBCG were followings; age 73±10 and 70±11; male/female 198/52 and 240/65 in KMSH and KMC, respectively. ReA was revealed in 5/250 (2.0%) and 6/305 (2.0%), uveitis in 3/250 (1.2%) and 1/305 (0.3%), and conjunctivitis in 18/250 (7.2%) and 15/305 (4.9%) in KMSH and KMC, respectively. As the total evaluation, ReA, uveitis and conjunctivitis were revealed in 11/555 (2.0%), 4/555 (0.7%) and 33/555(5.9%), respectively. All ReA were developed after 3-times of iBCG. Clinical, ultrasound and FDG-PET/CT findings of ReA induced by iBCG showed asymmetric polyarthritis/polyenthesitis. Laboratory examinations showed high CRP (>10mg/dl) in all cases. Notably, there were significant increased frequencies of HLA-B27, B35, B39 and B51 alleles in ReA patients (16.7%, 33.3%, 33.3% and 66.7%, respectively) when compared with healthy subjects (0.3%, 17.0%, 6.0% and 16.0%, respectively).

Conclusion:  Despite the positive rate of HLA-B27 in ReA induced by iBCG in our study was 16.7% suggesting lower frequency than 51 to 55% in the Western countries, the incidence of ReA induced by iBCG in Japanese population was 2.0 % which could be more than in the Western countries (0.5 to 1%) from previous reports. High positivity 66.7% and 33.3% of HLA-B51 and B39 in our study might raise the possibility that HLA-B51 or B39, besides B27, also may be associated with ReA induced by iBCG in Japan.


Disclosure: S. Inotani, None; Y. Taniguchi, None; T. Karashima, None; Y. Yoshinaga, None; H. Nishikawa, None; N. Maeda, None; S. Fujimoto, None; Y. Terada, None.

To cite this abstract in AMA style:

Inotani S, Taniguchi Y, Karashima T, Yoshinaga Y, Nishikawa H, Maeda N, Fujimoto S, Terada Y. Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/incidence-of-reactive-arthritis-uveitis-and-conjunctivitis-in-japanese-patients-with-bladder-cancer-following-intravesical-bcg-therapy-a-20-years-two-center-retrospective-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-reactive-arthritis-uveitis-and-conjunctivitis-in-japanese-patients-with-bladder-cancer-following-intravesical-bcg-therapy-a-20-years-two-center-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology